Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports
(2009) Symposium on Expanding the Boundaries of Clinical Practice - Building an Experience with Targeted Therapies 20. p.25-31- Abstract
- Background: Sunitinib malate is approved multinationally for the treatment of metastatic renal cell carcinoma (mRCC) and advanced imatinib-refractory gastrointestinal stromal tumour (GIST). Greater exposure to sunitinib is associated with improved efficacy. Therefore, minimising the impact of adverse events (AEs) on patient quality of life is important to enable patients to achieve optimal exposure to sunitinib and maximum clinical benefit. Design: This report describes four patient cases in which sunitinib was utilised for the management of advanced malignancies: two cases describe mRCC patients who received first-line sunitinib and two cases describe the use of targeted therapies, including sunitinib, in patients with advanced GIST.... (More)
- Background: Sunitinib malate is approved multinationally for the treatment of metastatic renal cell carcinoma (mRCC) and advanced imatinib-refractory gastrointestinal stromal tumour (GIST). Greater exposure to sunitinib is associated with improved efficacy. Therefore, minimising the impact of adverse events (AEs) on patient quality of life is important to enable patients to achieve optimal exposure to sunitinib and maximum clinical benefit. Design: This report describes four patient cases in which sunitinib was utilised for the management of advanced malignancies: two cases describe mRCC patients who received first-line sunitinib and two cases describe the use of targeted therapies, including sunitinib, in patients with advanced GIST. Results: In all four cases, effective AE management enabled patients to receive long-term therapy with sunitinib and achieve sustained clinical benefit. The two mRCC cases show prolonged responses and manageable AEs with sunitinib. The two GIST cases demonstrate that patients with imatinib-refractory GIST with KIT exon 9 mutations, including elderly patients, can achieve sustained responses to sunitinib. Conclusions: These case studies support the long-term efficacy and safety of sunitinib in the management of mRCC and imatinib-refractory GIST and demonstrate how AE management can be used to optimise patient responses. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1425428
- author
- Schoffski, P. ; Bukowski, R. ; Flodgren, Per LU and Ravaud, A.
- organization
- publishing date
- 2009
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- keywords
- sunitinib malate, gastrointestinal stromal tumour, metastatic renal cell carcinoma, tyrosine kinase inhibitor
- host publication
- Annals Of Oncology
- volume
- 20
- pages
- 25 - 31
- publisher
- Oxford University Press
- conference name
- Symposium on Expanding the Boundaries of Clinical Practice - Building an Experience with Targeted Therapies
- conference dates
- 2008-09-12
- external identifiers
-
- wos:000266497900005
- scopus:66549086138
- ISSN
- 0923-7534
- DOI
- 10.1093/annonc/mdp076
- language
- English
- LU publication?
- yes
- id
- caf52a58-46d7-44bf-8815-39a0c1493833 (old id 1425428)
- date added to LUP
- 2016-04-01 14:54:20
- date last changed
- 2022-01-28 03:04:32
@inproceedings{caf52a58-46d7-44bf-8815-39a0c1493833,
abstract = {{Background: Sunitinib malate is approved multinationally for the treatment of metastatic renal cell carcinoma (mRCC) and advanced imatinib-refractory gastrointestinal stromal tumour (GIST). Greater exposure to sunitinib is associated with improved efficacy. Therefore, minimising the impact of adverse events (AEs) on patient quality of life is important to enable patients to achieve optimal exposure to sunitinib and maximum clinical benefit. Design: This report describes four patient cases in which sunitinib was utilised for the management of advanced malignancies: two cases describe mRCC patients who received first-line sunitinib and two cases describe the use of targeted therapies, including sunitinib, in patients with advanced GIST. Results: In all four cases, effective AE management enabled patients to receive long-term therapy with sunitinib and achieve sustained clinical benefit. The two mRCC cases show prolonged responses and manageable AEs with sunitinib. The two GIST cases demonstrate that patients with imatinib-refractory GIST with KIT exon 9 mutations, including elderly patients, can achieve sustained responses to sunitinib. Conclusions: These case studies support the long-term efficacy and safety of sunitinib in the management of mRCC and imatinib-refractory GIST and demonstrate how AE management can be used to optimise patient responses.}},
author = {{Schoffski, P. and Bukowski, R. and Flodgren, Per and Ravaud, A.}},
booktitle = {{Annals Of Oncology}},
issn = {{0923-7534}},
keywords = {{sunitinib malate; gastrointestinal stromal tumour; metastatic renal cell carcinoma; tyrosine kinase inhibitor}},
language = {{eng}},
pages = {{25--31}},
publisher = {{Oxford University Press}},
title = {{Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports}},
url = {{http://dx.doi.org/10.1093/annonc/mdp076}},
doi = {{10.1093/annonc/mdp076}},
volume = {{20}},
year = {{2009}},
}